CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review

PloS One
Haris BabačićBenedikt Schoser

Abstract

The system of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (cas) is a new technology that allows easier manipulation of the genome. Its potential to edit genes opened a new door in treatment development for incurable neurological monogenic diseases (NMGDs). The aim of this systematic review was to summarise the findings on the current development of CRISPR-cas for therapeutic purposes in the most frequent NMGDs and provide critical assessment. We searched the MEDLINE and EMBASE databases, looking for original studies on the use of CRISPR-cas to edit pathogenic variants in models of the most frequent NMGDs, until end of 2017. We included all the studies that met the following criteria: 1. Peer-reviewed study report with explicitly described experimental designs; 2. In vitro, ex vivo, or in vivo study using human or other animal biological systems (including cells, tissues, organs, organisms); 3. focusing on CRISPR as the gene-editing method of choice; and 5. featured at least one NMGD. We obtained 404 papers from MEDLINE and 513 from EMBASE. After removing the duplicates, we screened 490 papers by title and abstract and assessed them for eligibility. After reading 50 full-text...Continue Reading

References

Sep 1, 1992·The Journal of Cell Biology·B A DanowskiJ W Sanger
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·P RouetM Jasin
Nov 1, 1996·The Journal of Cell Biology·I N RybakovaJ M Ervasti
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·R J ParksF L Graham
Aug 26, 1998·Brain : a Journal of Neurology·C E de Die-SmuldersJ P Geraedts
Jun 24, 2000·Journal of Reproduction and Fertility·E UbillaJ M Alvariño
Jul 4, 2001·Nucleic Acids Research·M FardaeiM G Hamshere
Jan 31, 2003·The Journal of Biological Chemistry·James M Ervasti
Sep 10, 2003·Cell Cycle·Grace K Pavlath, Valerie Horsley
Jul 17, 2004·The EMBO Journal·Thai H HoThomas A Cooper
Mar 29, 2005·Journal of Molecular Evolution·Francisco J M MojicaElena Soria
Mar 24, 2007·Science·Rodolphe BarrangouPhilippe Horvath
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Dec 1, 2009·Cell·Caryn R HaleMichael P Terns
Feb 24, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Chris Turner, David Hilton-Jones
Aug 21, 2010·Science·Richard J L F LemmersSilvère M van der Maarel
Oct 28, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Qi-Long LuTerence Partridge
Nov 5, 2010·Nature·Josiane E GarneauSylvain Moineau
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Aug 4, 2012·Neuromuscular Disorders : NMD·Jean Mathieu, Claude Prévost
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Giedrius GasiunasVirginijus Siksnys
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jan 24, 2013·European Journal of Human Genetics : EJHG·Stuart J MoatLouise Hartley
Jul 3, 2013·Current Opinion in Neurology·Felix Gövert, Susanne A Schneider
Jul 26, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·V CecinatiS Esposito
Jan 2, 2014·Nucleic Acid Therapeutics·Yusuke Echigoya, Toshifumi Yokota
Feb 18, 2014·RNA Biology·Gisle VestergaardShiraz A Shah
Mar 4, 2014·Nature Biotechnology·Jeffry D Sander, J Keith Joung
Jun 3, 2014·Biochimica Et Biophysica Acta·Giovanni Meola, Rosanna Cardani

❮ Previous
Next ❯

Citations

Feb 16, 2020·Nature Genetics·Masayuki NakamoriChristopher E Pearson
Aug 24, 2020·Trends in Biotechnology·Rongming LiuRyan T Gill
Oct 23, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kei NirasawaYoichi Negishi
Mar 2, 2021·Biochemical Pharmacology·Christopher L BarkauKeith T Gagnon
Aug 1, 2020·Progress in Retinal and Eye Research·Michael P FautschAlice E Davidson
Jun 4, 2021·The AAPS Journal·Amanda Catalina Ramirez-Phillips, Dexi Liu
Jul 3, 2021·International Journal of Molecular Sciences·Dito AnurogoJeanne Adiwinata Pawitan
Sep 9, 2021·Human Gene Therapy·Mario AmendolaEls Verhoeyen
Jan 27, 2022·Expert Review of Neurotherapeutics·Shaila D GhanekarTheresa A Zesiewicz

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
antisense oligonucleotides
transfection

Software Mentioned

ARRIVE
cas

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Biophysics of CRISPR

This feed focuses on broad characteristics of the CRISPR system and the proteins associated with it.